

**PATENT: CV01185K1X US**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Chackalamannil <i>et al.</i>	)	Group Art Unit:	1617
	)		
Serial No.: 10/705,282	)	Examiner:	Carlic K. Huynh
	)		
Filed: November 10, 2003	)	Confirmation No.:	4919
	)		
For: Methods of Use of Thrombin	)	Date:	May 12, 2008
Receptor Antagonists	)		
	)		
	)		

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450  
**Mailstop: RCE**

**AMENDMENT**

Sir:

This Amendment is being filed in response to the Final Office Action mailed on December 12, 2007. Because the Final Office Action raised issues related to those decided in another case owned by the Applicants, this Amendment is accompanied by an Information Disclosure Statement ("IDS") and associated Form PTO/SB/08b disclosing the complete file history of the other case, in accordance with the guidance given in McKesson Info. Solutions, Inc. v. Bridge Med. Inc., 487 F.3d 897 (Fed. Cir. 2007). Since this IDS is being filed after receipt of a Final Office Action, 37 CFR 1.97(d) applies, and requires that Applicants satisfy 37 CFR 1.97(e). Since Applicants could not make any of the statements in satisfaction of the requirements of 37 CFR 1.97(e), Applicants herewith file a Request for Continued Examination ("RCE"). Also filed herewith are two Terminal Disclaimers and a Request to Correct Inventorship under 37 C.F.R. §1.48(b).

Please amend the above-identified application as follows.

**Amendments to the Claims** are reflected in the listing of claims, which starts on page 2 of this paper.

**Remarks/Arguments** start on page 6 of this paper.